Lv74
4970 积分 2023-05-10 加入
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
1天前
待确认
Tarlatamab in relapsed small-cell lung cancer: a DLL3-targeted bispecific T-cell engager
2天前
已完结
Oncology Combination Drug Development Strategies for Project Optimus
4天前
已完结
Optimizing the FDA’s Project Optimus: opportunities and challenges
4天前
已完结
Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC
5天前
已完结
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
20天前
已完结
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study
20天前
已完结
Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial
29天前
已完结
Updated clinical practice guidelines for the management of adult diffuse gliomas
1个月前
已完结
A comprehensive review of immune checkpoint inhibitors for cancer treatment
1个月前
已完结
皖公网安备34019202002308
